Highlights

  • Archer Materials (ASX:AXE) continues to progress its biochip and Quantum Computing initiatives.
  • The company reported further development progress on its potassium biosensor program.
  • Archer strengthened its Balance Sheet through recent Capital raising activities.
  • The company remains focused on advancing early-stage deep technology platforms.

Archer Materials Limited (ASX:AXE) continues to develop its deep technology portfolio, with ongoing progress across its biochip diagnostics and quantum computing programs. The company remains focused on advancing its technology platforms towards future commercial applications.

At the time of writing on 25 August 2026, Archer Materials was trading at AUD 0.22, up 2.38%, as investors continued monitoring developments across the company’s technology initiatives and recent funding activities.

Technology Update

Archer Materials (ASX:AXE) recently provided an update on its potassium biosensor program, outlining progress from an early pre-pilot study.

The study involved 20 blood donors and compared conventional venous blood collection methods with several capillary or finger-prick collection techniques. The assessment focused on haemolysis levels, which can affect potassium measurements by releasing additional potassium into blood samples.

Archer identified a preferred capillary collection approach that produced haemolysis levels comparable with venous collection methods.

The company stated that the study was not a clinical validation program, with the biosensor remaining in a pre-pilot engineering stage as it moves towards an integrated Beta prototype.

Biochip Development

Following the pre-pilot study, Archer plans to combine the preferred blood collection method with processing and sensor components to test the complete workflow.

The company is targeting further development stages, including pilot studies, pivotal clinical studies and potential regulatory engagement later in 2026.

The biochip program remains focused on developing point-of-care diagnostic technology, with future milestones dependent on technical validation and regulatory progress.

Quantum Program

Alongside the biochip initiative, Archer continues to progress its quantum computing strategy.

The company entered into a Quantum Compute Agreement with IonQ in June 2026, providing access to quantum computing systems, future technology platforms, simulators and advisory services.

The collaboration is aimed at exploring quantum computing applications, including Archer’s Fraud detection program, and assessing opportunities related to sovereign quantum computing capability in Australia.

Archer’s quarterly update also outlined progress on its 12CQ quantum chip program, including completed full-wafer Manufacturing runs of a refined design.

Financial Position

Archer remains a pre-revenue technology developer, with ongoing Research and Development expenditure supporting its technology programs.

The company’s Appendix 4C for the quarter ended 30 June 2026 reported a cash balance of $8.406 million and no debt. Operating cash outflow during the quarter was $1.862 million, with total cash used of $1.927 million.

The company subsequently completed additional capital raising activities, including a $7 million Placement and a Share Purchase Plan that raised a further $953,000 at $0.27 per share.

The funds are intended to support quantum initiatives, the IonQ agreement and Working Capital requirements.

Market Focus

Investor attention on Archer Materials has centred on its dual technology strategy combining quantum computing and biochip development.

The Partnership with IonQ has provided the company with access to external quantum computing capability, while the biochip program continues to generate technical updates as development progresses.

Both platforms remain at early stages, with future market interest likely to depend on technical milestones, commercial progress and regulatory developments.

Growth Drivers

Potential growth drivers for Archer include advancement of its biochip platform, progress from the IonQ collaboration and continued development of its 12CQ quantum chip technology.

Successful technical validation, commercial partnerships or further application development could influence the company’s long-term pathway.

The strengthened cash position also provides additional support for ongoing research and development activities.

Key Risks

Archer Materials remains a pre-revenue company, and both its quantum and biochip programs involve significant technical and regulatory uncertainty.

The recent biosensor study was an early-stage engineering assessment rather than a clinical validation study, meaning further testing will be required before commercial applications can be assessed.

Additional funding requirements, development timelines and commercial adoption risks remain important considerations for the company.

What Comes Next?

Investors will monitor further progress on the biochip program, including integration of the preferred blood collection method into a beta prototype workflow.

The market will also watch developments from the IonQ collaboration, including quantum computing applications and potential future deployment opportunities.

Further quarterly updates are expected to provide additional information on cash position, research activities and project milestones.

Final Take

Archer Materials (ASX:AXE) continues to advance its quantum computing and biochip technology platforms through ongoing development activities and strategic partnerships. Recent progress across both programs provides further visibility into the company’s technology roadmap, although commercialisation remains dependent on technical validation, regulatory progress and future execution.